Sara M. Tolaney, MD, MPH

home / authors / sara-m-tolaney-md-mph

Articles

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

TPS 28 ELEGANT: Elacestrant VS Standard Endocrine Therapy in Women and Men With Node-Positive, Estrogen Receptor-Positive, HER2-Negative, Early Breast Cancer With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

Aditya Bardia, MD, MPH;Virginia Kaklamani, MD, DSc;Joyce A. O’Shaughnessy;Peter Schmid, MD;J. Thaddeus Beck,;Michelino De Laurentiis;Guiseppe Curigliano;Hope S. Rugo, MD;Carlos Barcenas;William J. Gradishar, MD;Michail Ignatiadis;David Cameron;Giulia Tonini;Simona Scartoni;Jennifer Crozier;Leo Viana Nicacio;Tomer Wasserman;Sara M. Tolaney, MD, MPH
June 18th 2025
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Marina Sharifi;Kristine Rinn;Wassim McHayleh;Rinat Yerushalmi;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Paula Muñoz Romero;Bartomeu Piza Vallespir;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 25th 2025
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Eva Ciruelos;Ji-Yeon Kim;Elena López-Miranda;Elia Seguí;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Alessandro Di Sanzo;Paula Muñoz Romero;Bartomeu Piza Vallespir;Manuel Dominguez;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 24th 2025
TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH;Paolo D’Amico;Liyi Jia;Kim M. Hirshfield;Fatima Cardoso
April 16th 2025
19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

19 Efficacy, Safety, and Quality of Life With Ribociclib + Endocrine Therapy in Elderly Patients With HR+/HER2– Advanced Breast Cancer Across the MONALEESA-2, -3, and -7 Trials

Lowell Hart;Seock-Ah Im;Sara M. Tolaney, MD, MPH;Mario Campone;Timothy Pluard;Berta Sousa;Gilles Freyer;Thomas Decker;Kevin Kalinsky, MD, MS;Astrid Thuerigen;Melissa Gao;Huilin Hu;Sherko Kümmel
August 9th 2024
20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

20 Final Overall Survival (OS) Analysis From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) in Patients (pts) With Hormone Receptor–Positive/HER2-Negative (HR+/HER2–) Metastatic Breast Cancer (mBC)

Sara M. Tolaney, MD, MPH;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortés, MD;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Oh Kyu Yoon;Hao Wang;Wendy Verret;Hope S. Rugo, MD
August 8th 2024
29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

29 ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Patients (pts) With Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–) Locally Advanced or Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sara M. Tolaney, MD, MPH;Virginia Kaklamani, MD, DSc;Paula Muñoz Romero;Shannon Matheny;Kathy Puyana Theall;Joyce A. O’Shaughnessy
July 21st 2024
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer

Matthew P. Goetz, MD;Masakazu Toi;Jens Huober, MD;Joohyuk Sohn;Oliver Trédan;In Hae Park;Mario Campone;Shin-Cheh Chen;Luis Manuel Manso;Shani Paluch-Shimon;Orit C. Freedman;Joyce A. O’Shaughnessy;Xavier Pivot;Sara M. Tolaney, MD, MPH;Sara A. Hurvitz, MD;Antonio Llombart;Valérie André;Abhijoy Saha;Gertjan van Hal;Ashwin Shahir;Hiroji Iwata;Stephen R.D. Johnston
June 23rd 2024
Sara M. Tolaney, MD, MPH, an expert on breast cancer

Clinical Pearls for the Treatment of Breast Cancer

Sara M. Tolaney, MD, MPH
October 26th 2023

Sara M. Tolaney, MD, MPH, concludes the program with advice for community oncologists who are treating patients with breast cancer.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

Emerging Therapies and Ongoing Trials in Breast Cancer

Sara M. Tolaney, MD, MPH
October 19th 2023

A breast oncologist looks to the future of breast cancer treatment and discusses emerging therapies and ongoing clinical trials.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

Treatment Landscape for Triple-Negative Breast Cancer

Sara M. Tolaney, MD, MPH
October 19th 2023

Expert perspectives on the treatment landscape for triple-negative breast cancer and the evolving role of immunotherapy in this space.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

Key Updates in Metastatic HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
October 12th 2023

Sara M. Tolaney, MD, MPH, reviews key clinical trial data recently updated in the metastatic HER2+ breast cancer treatment space.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

Evolving Treatment Landscape for HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
October 12th 2023

A medical oncologist offers clinical insights on the evolving treatment landscape for patients with HER2+ breast cancer.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

CDK4/6 & PARP Inhibitors for Early-Stage Breast Cancer

Sara M. Tolaney, MD, MPH
October 5th 2023

A comprehensive overview of the treatment landscape in early-stage breast cancer, with a focus on CDK4/6 and PARP inhibitors.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

The Role of Ki-67 and ctDNA as Prognostic or Predictive Markers in Breast Cancer

Sara M. Tolaney, MD, MPH
October 5th 2023

Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

Recent Updates for Biomarker Testing in Breast Cancer

Sara M. Tolaney, MD, MPH
September 28th 2023

Expert insights on biomarker testing in breast cancer, with a focus on key markers associated with specific subtypes.

Sara M. Tolaney, MD, MPH, an expert on breast cancer

The Overall Breast Cancer Landscape

Sara M. Tolaney, MD, MPH
September 28th 2023

Sara M. Tolaney, MD, MPH, an expert breast oncologist, reviews the overall treatment landscape for breast cancer.

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer

Sara M. Tolaney, MD, MPH
June 7th 2023

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

Sacituzumab Govitecan Provides More Treatment Options in HER2– Breast Cancer

Sara M. Tolaney, MD, MPH
June 5th 2023

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

Lisa A. Carey, MD;Tomas Pascual;Daniel Stover;Astrid Thuerigen;Charles Perou;Eva Ciruelos;Ana Casas;Patty Spears;Estelle Roux;Faye Su;Hullin Hu;Yen-Shen Lu;Sara M. Tolaney, MD, MPH;Ann H. Partridge, MD, MPH;Guillermo Villacampa;Juan Manuel Ferrero-Cafiero;Aleix Prat
April 28th 2023
48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

48 Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2– Negative (HR+/HER2–) Metastatic Breast Cancer (mBC) by HER2 Immunohistochemistry (IHC) Status in the Phase 3 TROPiCS-02 Study

Sara M. Tolaney, MD, MPH;Peter Schmid, MD;Javier Cortes;Frederik Marmé;Hope S. Rugo, MD;Mafalda Oliveira;Delphine Loirat;Komal Jhaveri;Oh Kyu Yoon;Monica Motwani;Hao Wang;Rosemary Delaney;Aditya Bardia, MD, MPH
April 27th 2023
53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

53 Overall Survival (OS) Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HR+/ HER2− Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Frederik Marmé;Javier Cortes;Peter Schmid, MD;Delphine Loirat;Olivier Trédan;Eva Ciruelos;Florence Dalenc;Patricia Gómez Pardo;Komal L. Jhaveri;Rosemary Delaney;Theresa Valdez;Hao Wang;Wendy Verret;Sara M. Tolaney, MD, MPH
April 27th 2023
54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

Hope S. Rugo, MD;Joyce O'Shaughnessy, MD;Komal Jhaveri;Sara M. Tolaney, MD, MPH;Fatima Cardoso;Aditya Bardia, MD, MPH;Purnima Pathak;Sina Haftchenary;Peter A. Fasching
April 26th 2023
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.

HER2 Expression Determines Benefit of Sacituzumab Govitecan in HR+ Breast Cancer

Sara M. Tolaney, MD, MPH
April 19th 2023

An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive, HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

Sacituzumab Govitecan Aids Unmet Need in Pretreated HR+, HER2– Breast Cancer

Sara M. Tolaney, MD, MPH
April 16th 2023

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Efficacy Makes Sacituzumab Govitecan ‘Attractive’ in Advanced Breast Cancer

Sara M. Tolaney, MD, MPH
April 13th 2023

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Govitecan Approval Gives ‘Meaningful’ Survival in Advanced HR+ Breast Cancer

Sara M. Tolaney, MD, MPH
February 3rd 2023

An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Experts on breast cancer

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS
January 27th 2023

Closing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.

Experts on breast cancer

Managing HER2+ Breast Cancer With Leptomeningeal Metastases

Sara M. Tolaney, MD, MPH;Nancy U. Lin, MD;Sarah Sammons, MD;Adrienne Waks, MD;Ayal A. Aizer, MD, MHS
January 27th 2023

Panelists center their discussion on the challenges inherent in managing leptomeningeal metastases in patients with HER2+ breast cancer.

12>

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: July 5th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes